KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Assets (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Non-Current Assets data on record, last reported at $11.2 million in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 15.51% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $48.1 million, up 178.47%, while the annual FY2025 figure was $11.2 million, 15.51% down from the prior year.
  • Non-Current Assets reached $11.2 million in Q4 2025 per AQST's latest filing, down from $11.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.6 million in Q1 2023 and bottomed at -$104.0 million in Q2 2024.
  • Average Non-Current Assets over 5 years is -$3.5 million, with a median of $13.3 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: crashed 367.94% in 2021, then surged 127.4% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $14.7 million in 2021, then grew by 16.61% to $17.2 million in 2022, then fell by 4.25% to $16.5 million in 2023, then fell by 19.74% to $13.2 million in 2024, then dropped by 15.51% to $11.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $11.2 million in Q4 2025, $11.9 million in Q3 2025, and $12.0 million in Q2 2025.